PDK1 and neoplasm: In 2005 the Dent laboratory published studies which strongly argued that the PDK-1 inhibitor OSU-03012 (licensed by Arno Therapeutics from Ohio State University and called AR-12) was not primarily acting as a PDK-1 inhibitor to radio-sensitize tumor cells [1, 2].